{"id":398438,"date":"2020-12-11T16:08:07","date_gmt":"2020-12-11T21:08:07","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=398438"},"modified":"2020-12-11T16:08:07","modified_gmt":"2020-12-11T21:08:07","slug":"kura-oncology-announces-closing-of-public-offering-and-full-exercise-of-option-to-purchase-additional-shares-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-announces-closing-of-public-offering-and-full-exercise-of-option-to-purchase-additional-shares-2\/","title":{"rendered":"Kura Oncology Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">SAN DIEGO, Dec.  11, 2020  (GLOBE NEWSWIRE) &#8212; Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the closing of its previously announced underwritten public offering of 9,326,500 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,216,500 shares, at a public offering price of $37.00 per share. The gross proceeds to Kura from the offering, before underwriting discounts and commissions and other offering expenses payable by Kura, were approximately $345.1 million.<\/p>\n<p align=\"justify\">SVB Leerink, Credit Suisse, Barclays and Stifel acted as joint bookrunning managers in the offering. Wedbush PacGrow, JMP Securities and H.C. Wainwright &amp; Co. acted as co-managers in the offering.<\/p>\n<p align=\"justify\">The securities described above were offered by Kura pursuant to a shelf registration statement on Form S-3, including a base prospectus, that was previously filed by Kura and became effective by rule of the Securities and Exchange Commission (the \u201cSEC\u201d) on December 7, 2020. A final prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available for free on the SEC\u2019s website located at http:\/\/www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained from: SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at (800) 808-7525, ext. 6132, or by email at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=VnT1jAaqNdiIzOn27WY8DfdsHgldIqFBx5R6tox9Ww9dlWtWOZ1bYMXhuygu7Q7AnEXc_CJX2vW7FTfTSmwFgWYx5AXtKyhPbYVsywEx0yI=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">syndicate@svbleerink.com<\/a>; Credit Suisse Securities (USA) LLC, Attention: Prospectus Department,\u00a06933 Louis Stephens Drive, Morrisville, NC 27560, by telephone at (800) 221-1037, or by email at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_Kj8R0US2R7unTxzvTDMDHHzimnQiCPMzZaI1J3ISPcwp7dRa-gSJeOQxbTo03FF1uONlF1KV-rbAQFSfJj6Ap5x69reasX-Lm8m_7B-6GkEEw6_4wpvL4drB-APp9_w\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>usa.prospectus@credit-suisse.com<\/u><\/a>; Barclays Capital Inc., c\/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by email at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=mLeW3iNDihCB4P3jcARZ5gmUrq-9l8IE1br-qqiqczC3lVi7JhAGmLJ6lV_V-A9iHnfFEakuhg_JgHWYZYwSzDQMm983hoyJV_jjauXyg_yMA9MmYhmzSAXwWa4frou_\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>barclaysprospectus@broadridge.com<\/u><\/a> or by telephone at (888) 603-5847; or Stifel, Nicolaus &amp; Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by email at <u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2yGk73M94f3dO-XdOgdLmanDtCNpyQ3AYWR4kRsl2PNEI6iN4Ac_za080T5JapjMR8PbGGcamy34ibQXK5G-2j0Yd0y-gsycaPXI7YMkioU=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">syndprospectus@stifel.com<\/a><\/u>\u00a0or by telephone at (415)\u00a0364-2720.<\/p>\n<p align=\"justify\">This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.<\/p>\n<p align=\"justify\">\n        <strong>About Kura Oncology<\/strong>\n      <\/p>\n<p align=\"justify\">Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company\u2019s pipeline consists of two wholly owned small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura\u2019s most advanced drug candidate is tipifarnib, a potent, selective and orally bioavailable farnesyl transferase inhibitor currently in a registration-directed trial (AIM-HN) in patients with recurrent or metastatic HRAS mutant head and neck squamous cell carcinoma. The Company\u2019s pipeline is also highlighted by KO-539, a potent and selective menin inhibitor currently in a Phase 1\/2A clinical trial (KOMET-001) in patients with relapsed or refractory acute myeloid leukemia.<\/p>\n<p align=\"start\">\n        <strong>Contacts<\/strong>\n      <\/p>\n<p align=\"start\">Company: <br \/> Pete De Spain <br \/> Vice President, Investor Relations &amp; <br \/> Corporate Communications <br \/> (858) 500-8803 <br \/> pete@kuraoncology.com<\/p>\n<p align=\"start\">Investors: <br \/> Robert H. Uhl <br \/> Managing Director <br \/> Westwicke ICR <br \/> (858) 356-5932 <br \/> robert.uhl@westwicke.com<\/p>\n<p align=\"start\">Media: <br \/> Jason Spark <br \/> Managing Director <br \/> Canale Communications <br \/> (619) 849-6005 <br \/> jason@canalecomm.com<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEwMDk5MiMzODY2NzczIzIwMTcxOTU=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/edc413e3-f041-407f-b1ed-c5c6cc6ac4ac\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO, Dec. 11, 2020 (GLOBE NEWSWIRE) &#8212; Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the closing of its previously announced underwritten public offering of 9,326,500 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,216,500 shares, at a public offering price of $37.00 per share. The gross proceeds to Kura from the offering, before underwriting discounts and commissions and other offering expenses payable by Kura, were approximately $345.1 million. SVB Leerink, Credit Suisse, Barclays and Stifel acted as joint bookrunning managers in the offering. Wedbush PacGrow, JMP Securities and H.C. Wainwright &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-announces-closing-of-public-offering-and-full-exercise-of-option-to-purchase-additional-shares-2\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Kura Oncology Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-398438","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Kura Oncology Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-announces-closing-of-public-offering-and-full-exercise-of-option-to-purchase-additional-shares-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kura Oncology Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, Dec. 11, 2020 (GLOBE NEWSWIRE) &#8212; Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the closing of its previously announced underwritten public offering of 9,326,500 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,216,500 shares, at a public offering price of $37.00 per share. The gross proceeds to Kura from the offering, before underwriting discounts and commissions and other offering expenses payable by Kura, were approximately $345.1 million. SVB Leerink, Credit Suisse, Barclays and Stifel acted as joint bookrunning managers in the offering. Wedbush PacGrow, JMP Securities and H.C. Wainwright &hellip; Continue reading &quot;Kura Oncology Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-announces-closing-of-public-offering-and-full-exercise-of-option-to-purchase-additional-shares-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-11T21:08:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEwMDk5MiMzODY2NzczIzIwMTcxOTU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kura-oncology-announces-closing-of-public-offering-and-full-exercise-of-option-to-purchase-additional-shares-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kura-oncology-announces-closing-of-public-offering-and-full-exercise-of-option-to-purchase-additional-shares-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Kura Oncology Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares\",\"datePublished\":\"2020-12-11T21:08:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kura-oncology-announces-closing-of-public-offering-and-full-exercise-of-option-to-purchase-additional-shares-2\\\/\"},\"wordCount\":566,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kura-oncology-announces-closing-of-public-offering-and-full-exercise-of-option-to-purchase-additional-shares-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEwMDk5MiMzODY2NzczIzIwMTcxOTU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kura-oncology-announces-closing-of-public-offering-and-full-exercise-of-option-to-purchase-additional-shares-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kura-oncology-announces-closing-of-public-offering-and-full-exercise-of-option-to-purchase-additional-shares-2\\\/\",\"name\":\"Kura Oncology Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kura-oncology-announces-closing-of-public-offering-and-full-exercise-of-option-to-purchase-additional-shares-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kura-oncology-announces-closing-of-public-offering-and-full-exercise-of-option-to-purchase-additional-shares-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEwMDk5MiMzODY2NzczIzIwMTcxOTU=\",\"datePublished\":\"2020-12-11T21:08:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kura-oncology-announces-closing-of-public-offering-and-full-exercise-of-option-to-purchase-additional-shares-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kura-oncology-announces-closing-of-public-offering-and-full-exercise-of-option-to-purchase-additional-shares-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kura-oncology-announces-closing-of-public-offering-and-full-exercise-of-option-to-purchase-additional-shares-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEwMDk5MiMzODY2NzczIzIwMTcxOTU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEwMDk5MiMzODY2NzczIzIwMTcxOTU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kura-oncology-announces-closing-of-public-offering-and-full-exercise-of-option-to-purchase-additional-shares-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kura Oncology Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kura Oncology Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-announces-closing-of-public-offering-and-full-exercise-of-option-to-purchase-additional-shares-2\/","og_locale":"en_US","og_type":"article","og_title":"Kura Oncology Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares - Market Newsdesk","og_description":"SAN DIEGO, Dec. 11, 2020 (GLOBE NEWSWIRE) &#8212; Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the closing of its previously announced underwritten public offering of 9,326,500 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,216,500 shares, at a public offering price of $37.00 per share. The gross proceeds to Kura from the offering, before underwriting discounts and commissions and other offering expenses payable by Kura, were approximately $345.1 million. SVB Leerink, Credit Suisse, Barclays and Stifel acted as joint bookrunning managers in the offering. Wedbush PacGrow, JMP Securities and H.C. Wainwright &hellip; Continue reading \"Kura Oncology Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-announces-closing-of-public-offering-and-full-exercise-of-option-to-purchase-additional-shares-2\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-11T21:08:07+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEwMDk5MiMzODY2NzczIzIwMTcxOTU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-announces-closing-of-public-offering-and-full-exercise-of-option-to-purchase-additional-shares-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-announces-closing-of-public-offering-and-full-exercise-of-option-to-purchase-additional-shares-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Kura Oncology Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares","datePublished":"2020-12-11T21:08:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-announces-closing-of-public-offering-and-full-exercise-of-option-to-purchase-additional-shares-2\/"},"wordCount":566,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-announces-closing-of-public-offering-and-full-exercise-of-option-to-purchase-additional-shares-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEwMDk5MiMzODY2NzczIzIwMTcxOTU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-announces-closing-of-public-offering-and-full-exercise-of-option-to-purchase-additional-shares-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-announces-closing-of-public-offering-and-full-exercise-of-option-to-purchase-additional-shares-2\/","name":"Kura Oncology Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-announces-closing-of-public-offering-and-full-exercise-of-option-to-purchase-additional-shares-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-announces-closing-of-public-offering-and-full-exercise-of-option-to-purchase-additional-shares-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEwMDk5MiMzODY2NzczIzIwMTcxOTU=","datePublished":"2020-12-11T21:08:07+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-announces-closing-of-public-offering-and-full-exercise-of-option-to-purchase-additional-shares-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-announces-closing-of-public-offering-and-full-exercise-of-option-to-purchase-additional-shares-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-announces-closing-of-public-offering-and-full-exercise-of-option-to-purchase-additional-shares-2\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEwMDk5MiMzODY2NzczIzIwMTcxOTU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEwMDk5MiMzODY2NzczIzIwMTcxOTU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-announces-closing-of-public-offering-and-full-exercise-of-option-to-purchase-additional-shares-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Kura Oncology Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/398438","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=398438"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/398438\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=398438"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=398438"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=398438"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}